Synercid, Zyvox Drug Pricing Discourages Use, IDSA Rep Says
Executive Summary
The cost of Aventis' Synercid and Pharmacia's Zyvox discourages use of the drugs for resistant disease pathogens, Infectious Disease Society of America representative Louis Rice, MD, Louis Stokes Cleveland Veterans Affairs Medical Center, told FDA's Anti-Infective Drugs Advisory Committee
You may also be interested in...
FDA Flexible With Accelerated Approval Evidence, Analysis Finds
Attorneys Sasinowski and Varond write that in some cases weak clinical evidence on the surrogate endpoint was not a barrier, but strong findings on unmet need and rarity usually are necessary for accelerated approval.
Antibiotic Research Stalling In Conversion Of Target Into New Drug
Translating validated targets into clinical candidates is the major hurdle in discovering new antibiotics to combat resistance, Lilly VP-Scientific Affairs Gail Cassell, PhD, suggested in a presentation to FDA's Center for Drug Evaluation & Research Jan. 7
Antibiotic Research Stalling In Conversion Of Target Into New Drug
Translating validated targets into clinical candidates is the major hurdle in discovering new antibiotics to combat resistance, Lilly VP-Scientific Affairs Gail Cassell, PhD, suggested in a presentation to FDA's Center for Drug Evaluation & Research Jan. 7